Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Ponesimod

(Ponvory®)

Ponvory®

Drug updated on 10/25/2024

Dosage FormTablet (oral; 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg)
Drug ClassSphingosine 1-phosphate receptor modulators
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • Ponesimod demonstrated a significant reduction in relapses over 24 months with a relative risk (RR) of 0.58 (95% CI (rate ratio [RR]: 0.47; 95% CI: 0.39-0.58) 0.48 to 0.70), indicating a 42% reduction in relapse risk for patients with relapsing multiple sclerosis. This is comparable to other drugs like Fingolimod (RR 0.54) and Dimethyl fumarate (RR 0.62).
  • Ponesimod reduced annualized relapse rates (ARR) by 53% (rate ratio [RR]: 0.47; 95% CI: 0.39-0.58) and also significantly reduced 12-week confirmed disability accumulation by 39% (hazard ratio [HR]: 0.61; 95% CI: 0.45-0.82), supporting its effectiveness in managing relapse and progression in relapsing multiple sclerosis.
  • Ponesimod's effectiveness is comparable to other disease-modifying therapies like Alemtuzumab and Natalizumab for relapse rate reduction and disability accumulation, positioning it as an effective option among S1P (RMS) receptor modulators for multiple sclerosis treatment.
  • Ponesimod was ranked worst among S1P receptor modulators for treatment acceptability, with a SUCRA (SUCRA 90.5%) score of 96.0%, indicating a higher likelihood of treatment discontinuation due to adverse events compared to other drugs.
  • There is no specific mention of serious adverse events (SAEs) for Ponesimod in the provided data. However, other drugs like Interferon beta-1b showed a possible trivial reduction in SAEs compared to placebo (OR (depending on the CDP definition used for included ofatumumab trials) 0.92, 95% CI 0.55 to 1.54).
  • The systematic review and network meta-analysis included 36,541 participants with relapsing-remitting multiple sclerosis (RRMS), of which 68.6% were female. No specific subgroup analyses were provided for Ponesimod, but a smaller relative treatment effect was noted in trials with a higher proportion of patients with prior disease-modifying therapy (DMT) usage.